The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of four new medicines in March, including specific actions around cancer therapies and label changes. CHMP endorsed two therapies for extended-stage small cell lung cancer, while also rebuffing an expanded label request for Vanda’s Hetlioz in Smith-Magenis syndrome, according to CHMP’s published opinions.